Amar Kishan
@AmarUKishan
Followers
4K
Following
7K
Media
36
Statuses
3K
Radiation Oncologist, Professor, and Executive Vice Chair of Radiation Oncology at UCLA. All views are my own.
Joined November 2017
It’s a pleasure to announce the appointment of Dr. @AmarUKishan to Executive Vice Chair for the Department of Radiation Oncology at the David Geffen School of Medicine at UCLA and the UCLA Jonsson Comprehensive Cancer Center.
16
3
111
RT @UclaUrology: We are thrilled to announce and welcome Dr @uroegg as the new chair of Urology at @UCLAHealth . A thought leader in @AmerU….
0
21
0
RT @JAMAOnc: Postoperative stereotactic body radiotherapy for prostate cancer was well-tolerated with similar urinary and bowel patient-rep….
0
3
0
RT @NiuSanford: Dr. D’Amico discusses his first clinical trial, RT+/- 6 mo ADT in unfavorable-risk prostate cancer (JAMA 2008). Such a gre….
0
12
0
RT @yuanjamesrao: US gov / DOE is posting about radiopharmaceuticals and alpha therapy! @freddyeescorcia #radonc.
0
5
0
RT @DrAndrewLoblaw: In my mind the highest quality evidence we have of RT compared to RP for high risk prostate cancer. Findings are very….
0
10
0
RT @DrYukselUrun: In high-risk prostate cancer, radiotherapy plus ADT significantly reduces the risk of distant metastasis compared to surg….
0
55
0
RT @SameerKeoleMD: Expanding the Scope of Radiation Therapy for Nonmalignant Diseases | ASTRO. If you are looking for a tour de force on th….
0
8
0
RT @weeloonong: Please join our esteemed international RO speakers in Melbourne in October for #RANZCR2025! Early bird registrations close….
0
4
0
RT @ebludmir: @ChadTangMD & I happy to report: ph2 basket EXTEND-OP trial has enrolled and randomized 150 patients in the last year since o….
0
12
0
RT @CZamboglou: Excited to share our newest paper on digital pathology AI biomarkers in prostate cancer RT. In this work we:. ▶️performed a….
0
16
0
@EurUrolOncol @JesusJ_MD @UCLAHealthJCCC Notably, the metachronous subgroup with prior ADT had worse outcomes, suggesting increasing resistance with repeated systemic therapy.
0
1
4
@EurUrolOncol @JesusJ_MD @UCLAHealthJCCC However, this may not be the case if measured from the time of M1 diagnosis. At least in the comparison of two prospective phase II trials, the synchronous omCSPC group had a significantly higher PSA response rate and significantly longer PFS and eugonadal PFS (p < 0.05).
1
0
2
@EurUrolOncol @JesusJ_MD @UCLAHealthJCCC Traditionally, de novo mHSPC is thought to follow a more aggressive natural history than oligorecurrent mHSPC, and this is certainly true if measured from time of initial diagnosis (i.e., time of initial diagnosis of non-metastatic disease for oligorecurrent mHSPC).
1
0
2
Great work out in @EurUrolOncol led by @JesusJ_MD outstanding PGY-5 @UCLAHealthJCCC . Pooled analysis of two trials of androgen annihilation (ADT+AAP+apa) and RP/RT plus MDT in de novo mHSPC or oligorecurrent mHSPC
euoncology.europeanurology.com
Patients with positron emission tomography–defined oligometastatic prostate cancer may achieve lasting disease control off treatment with restored testosterone after intensified therapy. Outcomes...
1
8
29
RT @APCCC_Lugano: Metformin for patients with metastatic prostate cancer starting androgen deprivation therapy: a randomised phase 3 trial….
0
31
0
RT @DrYukselUrun: Does hormone therapy (HT) after postop radiotherapy (RT) help in nonmetastatic prostate cancer?.🔘HT improves metastasis-f….
0
15
0
RT @DeepOnco: Delighted to share our comprehensive review on #ProstateCancer, now out in @CACancerJournal , the highest-impact STEM journal….
0
40
0
RT @APCCC_Lugano: Duration of Androgen Suppression with Postoperative Radiotherapy (DADSPORT) for Nonmetastatic Prostate Cancer: A Collabor….
0
68
0
RT @EUplatinum: 📢 New in European Urology @AmarUKishan et al:. 🎯 MRI-guided SBRT for prostate cancer significantly reduces late GU and GI t….
0
15
0